#United States #financial results #Envista Holdings #Brea #dental industry

Envista Holdings Corporation Reports First Quarter 2026 Results

Envista Holdings Corporation (NYSE: NVST) recently disclosed its financial results for the first quarter ending April 3, 2026. The company’s performance reflects a robust beginning to the year, with notable advancements in its strategic objectives.

Key Highlights from Q1 2026

CEO Paul Keel expressed satisfaction with the results, stating, "We delivered a good start to 2026, with significant core revenue growth of 9.5% compared to the same period last year. This growth translated into a remarkable 25% increase in adjusted EBITDA and a 50% increase in earnings per share (EPS)." This achievement demonstrates Envista's resilient customer engagement and successful introduction of new products into the market.

Financial Performance Overview

• - Sales: The company reported total sales of $706 million, accompanied by a 9.5% growth in core sales over the first quarter of 2025.
• - Profit Margins: Envista's GAAP diluted EPS reached $0.23, while adjusted diluted EPS soared to $0.36, marking a 50% year-on-year increase.
• - Net Income: The net income stood at $39 million, and adjusted EBITDA was reported at $99 million, reflecting a growth of 25% compared to last year, with a 14.0% adjusted EBITDA margin.

The positive results were further complemented by the ongoing contributions from the Envista Business System (EBS), which supported a gross margin increase of 100 basis points.

Strategic Business Highlights

Despite a backdrop of macroeconomic uncertainty, Envista's various business segments showcased commendable growth. The Specialty Products & Technologies segment reported an 8.4% increase in core sales, while the Equipment and Consumables segment led with a robust 11.5% growth.

The company emphasizes employee engagement and talent development, showcasing its commitment to social responsibility with the Envista Smile Project, which served over 3,700 patients in need.

Cash Flow and Share Repurchases

On the cash flow front, the operating cash flow for the quarter was negative $3 million, with free cash flow at negative $16 million. In light of these results, Envista repurchased approximately 1.6 million shares for about $43 million, with a remaining repurchase capacity of $41 million by the end of the quarter. Recently, the Board of Directors authorized an additional share repurchase program for $300 million, set to run through December 31, 2029.

Outlook for 2026

Looking ahead, Envista is maintaining its optimistic guidance for the full year 2026:

• - Core Sales Growth: Projected at 2% to 4%.
• - Adjusted EBITDA Growth: Expected between 7% and 13%.
• - Adjusted Diluted EPS: Forecasted to lie between $1.35 and $1.45, with a free cash conversion target of approximately 100%.

As the company gears up for the remainder of the year, it will discuss its quarterly results in detail during an investor conference call on May 6, 2026. Investors can access the call through the investor section of Envista's website.

About Envista Holdings Corporation

Envista is a leading entity in the dental sector, uniting over 30 well-known brands like DEXIS, Kerr, Nobel Biocare, and Ormco. The company’s mission is rooted deeply in supporting dental professionals to enhance patient care, building upon a foundation of innovative products and technologies. Envista's commitment to excellence is exemplified through its high-performing culture guided by core values, ensuring it continues to deliver effective solutions that shape the future of dental care.

To stay updated on Envista's latest developments, visit Envista's website.